BackgroundSacubitril/valsartan is an effective treatment for heart failure with reduced ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or impact in real-world practice. The aim of this study was to describe our routine clinical experience of switching otherwise optimally treated patients with HFrEF to sacubitril/valsartan with respect to patient outcomes such as quality of life (QoL) and echocardiographic variables.Methods and resultsFrom June 2017 to May 2019, 80 consecutive stable patients with HFrEF on established and maximally tolerated guideline-directed HF therapies were initiated on sacubitril/valsartan with bimonthly uptitration. Clinical assessment, biochemistry, echocardiography and QoL were compared pretreatment and post-treatment switching. We were able to successfully switch 89% of patients from renin–angiotensin axis inhibitors to sacubitril/valsartan (71 of 80 patients). After 3 months of switch therapy, we observed clinically significant and incremental improvements in blood pressure (systolic blood pressure 123 vs 112 mm Hg, p<0.001; diastolic blood pressure 72 vs 68 mm Hg, p=0.004), New York Heart Association functional classification score (2.3 vs 1.9, p<0.001), Minnesota Living with Heart Failure Questionnaire score (46 vs 38, p=0.016), left ventricular ejection fraction (26% vs 33%, p<0.001) and left ventricular end systolic diameter (5.2 vs 4.9 cm, p=0.013) compared with baseline. There were no significant changes in renal function or serum potassium.ConclusionThis study provides real-world clinical practice data demonstrating incremental improvements in functional and echocardiographic outcomes in optimally treated patients with HFrEF switched to sacubitril/valsartan. The data provide evidence beyond that observed in clinical trial settings of the potential benefits of sacubitril/valsartan when used as part of a multidisciplinary heart failure programme.

Background Temporary cardiac pacing, conventionally achieved using a passive transvenous pacing wire, can be life‐saving for unstable arrhythmias. However, they run the risk of complications, the longer they remain in‐situ. Externalized prolonged temporary pacing (EPTP), using active‐fixation lead and an externalized pulse generator; may be an alternative for transient pacing indications, concurrent illness or sepsis that precludes permanent pacing. Methods Sixty‐seven patients (mean age 69 ± 14 years; 82% male) underwent EPTP between November 2011 and April 2019. EPTP was performed in a sterile facility, under fluoroscopy, using active‐fixation leads anchored to the right ventricle septum. Externalized lead was connected to a re‐sterilized pulse generator and secured to anterior chest wall with transparent dressings. EPTP indications and patient outcomes were evaluated. Results Pacing indications were high‐grade atrio‐ventricular (AV) block (73.2%), sinus arrest (14.9%), overdrive suppression of VT (5.9%) and pause‐dependent VT (4.5%). Reasons for ETPT rather than permanent pacing included: sepsis (38.8%), CIED‐related infection (8.9%), transient pacing indication (25%), to allow further investigations prior to decision on CIED type (22%), and over‐drive arrhythmia suppression (6%). Sixty three percent patients were severely ill in an ICU. Mean duration of pacing was 16 ± 12 days. Sixty seven percent patients subsequently received a CIED and had no evidence of device‐related infection at 1‐year post‐implant. There were three non‐fatal complications during EPTP while no deaths were attributed to EPTP. Conclusion EPTP is a safe and useful method of prolonged temporary pacing for patients who require chronotropic support, but in whom immediate permanent pacemaker implantation is contraindicated.

No abstract

No abstract

Objective Revision to cardiac resynchronisation therapy (CRT) in patients with existing pacemakers with worsening heart failure (HF) can improve symptoms and cardiac function. We identify factors that predict improvement in left ventricular ejection fraction (LVEF) within a year of CRT revision. Methods We performed a retrospective study of 146 consecutive patients (16% female, mean age 73 ± 11 years, mean LVEF 27 ± 8%) undergoing revision to CRT (January 2012 to May 2018) in a single tertiary centre. LVEF was measured pre-revision and 3, 6 and 12 months post-upgrade. Results At 6 months, 68% of patients demonstrated improvement in LVEF (mean ΔLVEF + 6.7% ± 9.6). Compared to patients in atrial fibrillation (AF), patients with sinus rhythm had a greater improvement in LVEF at 6 months (sinus 8.4 ± 10.3% vs. AF 4.2 ± 8.0%, p = 0.02). Compared to ischaemic cardiomyopathy (ICM), patients with non-ischaemic cardiomyopathy (NICM) had a greater improvement in LVEF at 6 months (NICM 8.4 ± 9.8% vs ICM 4.8 ± 9.2%, p = 0.05). Patients with RV pacing ≥40% at baseline had a greater improvement in LVEF at 6 months (≥40% RV pacing 9.3 ± 10.2 vs. < 40% RV pacing 4.0 ± 7.4%, p = 0.01). All improvements were sustained over 12 months post-revision. There was no significant difference between genders, years between initial implant and revision, or previous device type. Conclusions Our real-world experience supports current guidelines on CRT revision. NICM, ≥40% RV pacing and sinus rhythm are the main predictors of improvement in LVEF in patients who underwent CRT revision.

No abstract

were 142 HFpEF patients (73±7 years, 74% female), 725 HTN controls (70±7 years, 49% female) and 205 healthy controls (67±5 years, 59% female) (Table 1).There was a significant correlation between TAC and height in the participants as a group (r=0.218, p<0.001; Figure 1A). By sex-groups, a correlation between TAC and height was seen in HTN men only (r=0.149; p=0.004; Figure 1B), with no correlation seen in women (r=0.068, p=0.106; Figure 1C).Height was only an independent predictor of TAC when controlling for sex in HTN controls (b=0.11, p=0.047). Women were shorter than men (p<0.001 for all groups) and had significantly higher Ea and lower TAC, except in the HFpEF group. Men with HFpEF were shorter than male healthy controls (p<0.05). In healthy men and men with hypertension, taller stature was associated with lower Ea and TAC (b=0.125, p=0.019). Conclusions Women have significantly higher Ea and lower TAC. In both men and women with hypertension, a taller stature was independently associated with reduced pulsatile arterial load and Ea. Women are more susceptible to the deleterious effects of low TAC, which may partly explain the sex differences in the prevalence of HFpEF.

SIR and the pick-up rate for asymptomatic SIR at three years was 98.3% and 98.7% (pϭ0.456), 82% and 83.5%(pϭ0.876) and 48% (nϭ33/68) and 45%(nϭ25/ 56)(pϭ0.34) respectively in protocol I and II. The two protocols initiated asymptomatic SIR in 7.5% of patients (mean 197; 35-1543 days). Symptomatic SIRs are more likely to occur within 30-day (mean 22; 1-1132 days) from the deployment.Conclusions: Our study showed that the type of surveillance imaging modality did not appear to influence the SIR rate while symptoms still trigger a significant rate of SIR following EVAR.